Research map: Targeting the Menin–KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success.

Back to the article

Papers in this map

  1. Inhibitors of Protein Methyltransferases and Demethylases · H. Ümit Kanıskan · 2017 · 309 citations · Cited by this paper
  2. KMT2A-Partial Tandem Duplication associates with leukemia transformation in myelodysplastic syndrome · 2026 · Related
  3. Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) · Ghayas C. Issa · 2024 · 232 citations · Cited by this paper
  4. Bispecific Antibody Therapy With Elranatamab for Refractory Waldenström Macroglobulinemia: A Case Report · 2026 · Related
  5. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside · Byung‐Sik Cho · 2017 · 97 citations · Cited by this paper
  6. Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management · 2026 · Related
  7. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML · Bing Z. Carter · 2021 · 76 citations · Cited by this paper
  8. Treatment modalities and the impact of granulocyte colony-stimulating factor in AML patients treated with venetoclax and azacitidine: A DATAML registry study · 2026 · Related
  9. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia · Anna Candoni · 2024 · 73 citations · Cited by this paper
  10. Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies · 2026 · Related
  11. Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors · Juan Martin Barajas · 2023 · 64 citations · Cited by this paper
  12. SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis · 2026 · Related
  13. Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia · Xinyue Zhou · 2024 · 48 citations · Cited by this paper
  14. SOHO State of the Art Updates and Next Questions | Best of Stem Cell Transplant: Recent Advances in Allogeneic Hematopoietic Cell Transplantation · 2026 · Related
  15. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1 -Mutated or KMT2A -Rearranged AML · Joshua F. Zeidner · 2025 · 45 citations · Cited by this paper
  16. The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML · Milad Rasouli · 2023 · 44 citations · Cited by this paper
  17. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor · Warren C. Fiskus · 2024 · 44 citations · Cited by this paper
  18. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies · Sara Zehtabcheh · 2025 · 43 citations · Cited by this paper
  19. Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML · Eunice S. Wang · 2025 · 41 citations · Cited by this paper
  20. Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study · Jeffrey E. Lancet · 2023 · 32 citations · Cited by this paper
  21. Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions · Florian Perner · 2025 · 22 citations · Cited by this paper
  22. Drug-resistant menin variants retain high binding affinity and interactions with MLL1 · Joshua M. Ray · 2024 · 19 citations · Cited by this paper
  23. Disparate leukemia mutations converge on nuclear phase-separated condensates · Gandhar K. Datar · 2025 · 19 citations · Cited by this paper
  24. Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents · Adriane Halik · 2022 · 18 citations · Cited by this paper
  25. Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions · Sandhya Dhiman · 2024 · 15 citations · Cited by this paper
  26. Menin: from molecular insights to clinical impact · Margaret R. Brown · 2025 · 15 citations · Cited by this paper
  27. The promise of menin inhibitors: from approval to triplet regimens · Rahul Thakur · 2025 · 11 citations · Cited by this paper
  28. Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia · Fei Xie · 2025 · 10 citations · Cited by this paper
  29. Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure · Kuo‐Kai Chin · 2025 · 9 citations · Cited by this paper
  30. Combination Strategies with Menin Inhibitors for Acute Leukemia · Ghayas C. Issa · 2025 · 8 citations · Cited by this paper
  31. A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias · Jayastu Senapati · 2025 · 7 citations · Cited by this paper
  32. Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review · Martina Canichella · 2025 · 7 citations · Cited by this paper
  33. Inside the Battle Against Acute Myeloid Leukemia: Biology, Breakthroughs, and Hope · Jiayang Bao · 2026 · 7 citations · Cited by this paper
  34. Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy · Wusixian Huang · 2025 · 6 citations · Cited by this paper
  35. Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise · Utsav Joshi · 2026 · 6 citations · Cited by this paper
  36. Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia · Kuo‐Kai Chin · 2026 · 6 citations · Cited by this paper
  37. Development of DOT1L-Targeted Protein Degraders for Treating MLL-r Leukemia · Songhua Quan · 2026 · 5 citations · Cited by this paper
  38. NPM1-Mutated AML: Deciphering the Molecular and Clinical Puzzle in the Era of Novel Treatment Strategies · Michael D. Diamantidis · 2025 · 4 citations · Cited by this paper
  39. Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives · Tiffany Chen · 2026 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)